Revance Therapeutics Inc [NASDAQ: RVNC] closed the trading session at $6.58.
The stocks have a year to date performance of -25.14 percent and weekly performance of 0.00 percent. The stock has been moved at 1.23 percent over the last six months. The stock has performed 115.03 percent around the most recent 30 days and changed 126.12 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 3.72M shares, RVNC reached to a volume of 3552667 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Revance Therapeutics Inc [RVNC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RVNC shares is $10.16 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RVNC stock is a recommendation set at 2.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Revance Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 29, 2024. While these analysts kept the previous recommendation, Goldman raised their target price from $30 to $8. The new note on the price target was released on January 09, 2024, representing the official price target for Revance Therapeutics Inc stock. Previously, the target price had yet another raise to $20, while Exane BNP Paribas analysts kept a Neutral rating on RVNC stock.
The Average True Range (ATR) for Revance Therapeutics Inc is set at 0.19, with the Price to Sales ratio for RVNC stock in the period of the last 12 months amounting to 2.81.
RVNC stock trade performance evaluation
Revance Therapeutics Inc [RVNC] fell into the red zone at the end of the last week, falling into a negative trend and dropping by 0.00. With this latest performance, RVNC shares gained by 115.03% in over the last four-week period, additionally plugging by 1.23% over the last 6 months – not to mention a drop of -63.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RVNC stock in for the last two-week period is set at 76.19, with the RSI for the last a single of trading hit 79.64, and the three-weeks RSI is set at 72.74 for Revance Therapeutics Inc [RVNC]. The present Moving Average for the last 50 days of trading for this stock 4.40, while it was recorded at 6.58 for the last single week of trading, and 5.08 for the last 200 days.
Revance Therapeutics Inc [RVNC]: An insightful look at the core fundamentals
Revance Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.01 and a Current Ratio set at 3.74.
Earnings per share (EPS) analysis for Revance Therapeutics Inc [RVNC] stock
With the latest financial reports released by the company, Revance Therapeutics Inc posted -1.63/share EPS, while the average EPS was predicted by analysts to be reported at -0.85/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.78. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RVNC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Revance Therapeutics Inc go to 11.60%.
Revance Therapeutics Inc [RVNC]: Institutional Ownership
There are presently around $84.77%, or 92.72%% of RVNC stock, in the hands of institutional investors. The top three institutional holders of RVNC stocks are: CAPITAL WORLD INVESTORS with ownership of 13.94 million shares, which is approximately 15.164%. BLACKROCK INC., holding 8.57 million shares of the stock with an approximate value of $$22.01 million in RVNC stocks shares; and BLACKROCK INC., currently with $$16.09 million in RVNC stock with ownership which is approximately 6.8092%.
